Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and
the correlation among them.
10.11817/j.issn.1672-7347.2015.09.005
- Author:
Xinjun LI
1
,
2
;
Qingyuan WANG
3
;
Limei FU
4
;
Min LIU
4
;
Xuemei YU
4
Author Information
1. Department of Pathology, Binzhou People's Hospital, Binzhou Shandong 256610, China lixinjunhe@
2. com.
3. Department of Science and Education, Binzhou People's Hospital, Binzhou Shandong 256610, China.
4. Department of Pathology, Binzhou People's Hospital, Binzhou Shandong 256610, China.
- Publication Type:Journal Article
- MeSH:
Breast Neoplasms;
classification;
metabolism;
pathology;
Carcinoma, Ductal, Breast;
metabolism;
pathology;
Female;
Humans;
Lymphatic Metastasis;
PTEN Phosphohydrolase;
metabolism;
Receptor, ErbB-2;
metabolism;
Receptors, Estrogen;
metabolism;
Receptors, Progesterone;
metabolism;
Triple Negative Breast Neoplasms;
metabolism;
pathology;
Tumor Suppressor Protein p53;
metabolism
- From:
Journal of Central South University(Medical Sciences)
2015;40(9):973-978
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the expression of PTEN, p53 and epidermal growth factor receptor (EGFR) in the molecular subtypes of breast carcinoma and to evaluate the correlations with triple-negative breast cancer.
METHODS:Immunohistochemical MaxVision(TM) method was used to detect the expression of PTEN, p53, EGFR, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in 291 cases of infiltrating ductal carcinoma of breast.
RESULTS:The positive expression of PTEN, p53 and EGFR protein in breast carcinoma was 57.0%, 57.0% and 38.5%, respectively, which were significantly different from those in benign breast diseases (P<0.05). The expression of PTEN or EGFR in breast cancer was correlated with tumor size, histological grade, lymph node metastasis, TNM stage, ER and HER2 status (P<0.05); the expression of p53 was correlated with tumor size, histological grade and ER status (P<0.05). The difference of positive expression rates of PTEN, p53 and EGFR protein among different subtypes including luminal A, luminal B (HER2-), luminal B (HER2+), HER2 over-expression and triple-negative was statistically significant (P<0.05). There were close correlations among PTEN, p53 and EGFR in the triple-negative subtype (P<0.05).
CONCLUSION:Low expression of PTEN and high expression of EGFR and p53 are observed in triple-negative breast cancer, which may synergistically contribute to the pathogenesis of triple-negative breast cancer.
